Charles Schwab Investment Management Inc. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,471,849 shares of the medical equipment provider's stock after selling 55,252 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.65% of Hologic worth $106,106,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of HOLX. Swedbank AB raised its holdings in Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock valued at $157,788,000 after acquiring an additional 306,562 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Hologic by 27.4% during the third quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical equipment provider's stock valued at $164,000 after purchasing an additional 434 shares during the period. Van ECK Associates Corp acquired a new position in shares of Hologic in the third quarter valued at $725,000. Principal Financial Group Inc. lifted its position in Hologic by 3.6% in the third quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider's stock worth $21,957,000 after purchasing an additional 9,419 shares during the period. Finally, Equitable Trust Co. acquired a new stake in Hologic during the third quarter worth $252,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.
Hologic Trading Down 0.6 %
HOLX traded down $0.39 during mid-day trading on Thursday, reaching $60.71. The stock had a trading volume of 1,817,696 shares, compared to its average volume of 2,353,431. The firm's fifty day simple moving average is $67.65 and its two-hundred day simple moving average is $74.94. The stock has a market capitalization of $13.62 billion, a P/E ratio of 19.15, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $60.33 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.
Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.
Analyst Upgrades and Downgrades
HOLX has been the topic of several recent research reports. Evercore ISI decreased their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Wolfe Research started coverage on Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating on the stock. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price for the company. Finally, StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $84.62.
Get Our Latest Stock Analysis on Hologic
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Articles
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
